Recursion Pharmaceuticals Inc. (RXRX) News
Filter RXRX News Items
RXRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RXRX News Highlights
- RXRX's 30 day story count now stands at 5.
- Over the past 7 days, the trend for RXRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, MAPS and MO are the most mentioned tickers in articles about RXRX.
Latest RXRX News From Around the Web
Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.
Recursion to Participate in Upcoming Investor ConferenceRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference: |
Bears are Losing Control Over Recursion Pharmaceuticals (RXRX), Here's Why It's a 'Buy' NowAfter losing some value lately, a hammer chart pattern has been formed for Recursion Pharmaceuticals (RXRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D DayRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry. Just as a regular map is a navigation tool in the physical world, Recursion's maps are designed to help scientists understand the topology and connectedness of human biology and chemistry to navigate the path to new medicines mo |
Recursion Pharmaceuticals (RXRX) Upgraded to Buy: What Does It Mean for the Stock?Recursion Pharmaceuticals (RXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in Recursion Pharmaceuticals (RXRX)? Wall Street Analysts Think 53.67%The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Institutional investors may adopt severe steps after Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) latest 7.4% drop adds to a year lossesTo get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to... |
Recursion to Participate in Upcoming Investor ConferencesRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: |
Forecast: Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Business Prospects Have Improved DrasticallyRecursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) shareholders will have a reason to smile today, with the analysts... |
Recursion Pharmaceuticals Third Quarter 2022 Earnings: Beats ExpectationsRecursion Pharmaceuticals ( NASDAQ:RXRX ) Third Quarter 2022 Results Key Financial Results Revenue: US$13.2m (up 419... |
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue EstimatesRecursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 2.78% and 104.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |